Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 304

1.

Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity.

Tolba KA, Bowers WJ, Muller J, Housekneckt V, Giuliano RE, Federoff HJ, Rosenblatt JD.

Cancer Res. 2002 Nov 15;62(22):6545-51.

2.

T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy.

Kirk CJ, Hartigan-O'Connor D, Nickoloff BJ, Chamberlain JS, Giedlin M, Aukerman L, Mule JJ.

Cancer Res. 2001 Mar 1;61(5):2062-70.

3.

Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.

Flanagan K, Glover RT, Hörig H, Yang W, Kaufman HL.

Vaccine. 2004 Jul 29;22(21-22):2894-903.

PMID:
15246626
4.

Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo.

Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, Zhu LX, Batra RK, Dubinett SM.

J Immunol. 2000 May 1;164(9):4558-63.

5.
6.
7.

Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT.

Hisada M, Yoshimoto T, Kamiya S, Magami Y, Miyaji H, Yoneto T, Tamada K, Aoki T, Koyanagi Y, Mizuguchi J.

Cancer Gene Ther. 2004 Apr;11(4):280-8.

PMID:
15002032
8.

Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.

Liu Y, Zhang X, Zhang W, Chen Z, Chan T, Ali K, Jia Z, Xiang J.

Cancer Gene Ther. 2002 Feb;9(2):202-8.

9.
10.

Combined HSV-TK/GCV and secondary lymphoid tissue chemokine gene therapy inhibits tumor growth and elicits potent antitumor CTL response in tumor-bearing mice.

Warren P, Song W, Holle E, Holmes L, Wei Y, Li J, Wagner T, Yu X.

Anticancer Res. 2002 Mar-Apr;22(2A):599-604.

PMID:
12014627
11.

CD40 ligand promotes priming of fully potent antitumor CD4(+) T cells in draining lymph nodes in the presence of apoptotic tumor cells.

Fujita N, Kagamu H, Yoshizawa H, Itoh K, Kuriyama H, Matsumoto N, Ishiguro T, Tanaka J, Suzuki E, Hamada H, Gejyo F.

J Immunol. 2001 Nov 15;167(10):5678-88.

12.

Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity.

Yang SC, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M, Atianzar K, Kuo BY, Gardner B, Batra RK, Strieter RM, Dubinett SM, Sharma S.

Clin Cancer Res. 2004 Apr 15;10(8):2891-901.

13.

Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.

Knippertz I, Hesse A, Schunder T, Kämpgen E, Brenner MK, Schuler G, Steinkasserer A, Nettelbeck DM.

J Immunother. 2009 Jun;32(5):524-38. doi: 10.1097/CJI.0b013e3181a28422.

PMID:
19609245
14.

Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms.

Vicari AP, Ait-Yahia S, Chemin K, Mueller A, Zlotnik A, Caux C.

J Immunol. 2000 Aug 15;165(4):1992-2000.

15.
16.
17.

Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery.

Koya RC, Kasahara N, Favaro PM, Lau R, Ta HQ, Weber JS, Stripecke R.

J Immunother. 2003 Sep-Oct;26(5):451-60.

PMID:
12973034
18.
19.
20.

Dendritic and tumor cell fusions transduced with adenovirus encoding CD40L eradicate B-cell lymphoma and induce a Th17-type response.

Alvarez E, Moga E, Barquinero J, Sierra J, Briones J.

Gene Ther. 2010 Apr;17(4):469-77. doi: 10.1038/gt.2009.150.

PMID:
20010627

Supplemental Content

Support Center